LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Suletud

SektorTervishoid

433.1 -0.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

432.05

Max

438.16

Põhinäitajad
By Trading Economics
Sissetulek	-160M 1B
Müük	-240M 3B
P/E Sektori keskmine	25.91 49.701
Aktsiakasum	4.47
Kasumimarginaal	34.531
Töötajad	6,400
EBITDA	-215M 1.1B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.84% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. aug 2026

Turustatistika
By TradingEconomics
Turukapital	2.4B 111B
Eelmine avamishind	433.14
Eelmine sulgemishind	433.1

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

428.545 / 498.65 Toetus ja vastupanu

Vertex Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 20:57 UTC

Tulu

Vertex Pharmaceuticals Posts Higher 1Q Profit

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3. nov 2025, 21:44 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5. aug 2025, 00:05 UTC

Kuumad aktsiad

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4. aug 2025, 21:21 UTC

Tulu

Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. mai 2026, 20:02 UTC

Tulu

Vertex Pharmaceuticals Reiterates 2026 Guidance

4. mai 2026, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4. mai 2026, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4. mai 2026, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4. mai 2026, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12. veebr 2026, 21:13 UTC

Tulu

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12. veebr 2026, 21:13 UTC

Tulu

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12. veebr 2026, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12. veebr 2026, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12. veebr 2026, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12. veebr 2026, 21:01 UTC

Tulu

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3. nov 2025, 21:05 UTC

Tulu

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. nov 2025, 21:02 UTC

Tulu

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3. nov 2025, 21:02 UTC

Tulu

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3. nov 2025, 21:02 UTC

Tulu

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3. nov 2025, 21:02 UTC

Tulu

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5. aug 2025, 20:44 UTC

Tulu

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 18:17 UTC

Tulu

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 15:25 UTC

Tulu

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. aug 2025, 14:12 UTC

Tulu

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5. aug 2025, 11:27 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:55 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:36 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:18 UTC

Tulu

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Vertex Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

29.84% tõus

12 kuu keskmine prognoos

Keskmine 562.9 USD 29.84%

Kõrge 641 USD

Madal 436 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Vertex Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

24 ratings

Osta

Hoia

Müü

Põhineb 24 analüütiku instrumendi Vertex Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

428.545 / 498.65Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.